Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Smoking affects the interferon beta treatment response in multiple sclerosis.

Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sørensen PS, Sellebjerg F, Søndergaard HB.

Neurology. 2018 Feb 13;90(7):e593-e600. doi: 10.1212/WNL.0000000000004949. Epub 2018 Jan 17.

PMID:
29343473
2.

Disability in progressive MS is associated with T2 lesion changes.

Ammitzbøll C, Dyrby TB, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, Iversen P, Magyari M, Garde E, Sørensen PS, Siebner HR, Sellebjerg F.

Mult Scler Relat Disord. 2017 Dec 18;20:73-77. doi: 10.1016/j.msard.2017.12.010. [Epub ahead of print]

PMID:
29324249
3.

Psychiatric morbidity develops after onset of pediatric multiple sclerosis: A Danish nationwide population-based study.

Boesen MS, Thygesen LC, Uldall PV, Eriksson F, Born AP, Blinkenberg M, Koch-Henriksen N, Greisen G, Magyari M.

Mult Scler Relat Disord. 2018 Jan;19:30-34. doi: 10.1016/j.msard.2017.10.018. Epub 2017 Oct 31.

PMID:
29121513
4.

Male factor infertility and risk of multiple sclerosis: A register-based cohort study.

Glazer CH, Tøttenborg SS, Giwercman A, Bräuner EV, Eisenberg ML, Vassard D, Magyari M, Pinborg A, Schmidt L, Bonde JP.

Mult Scler. 2017 Oct 1:1352458517734069. doi: 10.1177/1352458517734069. [Epub ahead of print]

PMID:
29027840
5.

Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.

Thormann A, Sørensen PS, Koch-Henriksen N, Laursen B, Magyari M.

Neurology. 2017 Oct 17;89(16):1668-1675. doi: 10.1212/WNL.0000000000004508. Epub 2017 Sep 20.

PMID:
28931645
6.

Excess mortality among patients with multiple sclerosis in Denmark has dropped significantly over the past six decades: a population based study.

Koch-Henriksen N, Laursen B, Stenager E, Magyari M.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):626-631. doi: 10.1136/jnnp-2017-315907.

PMID:
28705951
7.

Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study.

Boesen MS, Magyari M, Koch-Henriksen N, Thygesen LC, Born AP, Uldall PV, Blinkenberg M.

Mult Scler. 2017 Jun 1:1352458517713669. doi: 10.1177/1352458517713669. [Epub ahead of print]

PMID:
28608742
8.

Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships.

Thormann A, Sørensen PS, Koch-Henriksen N, Thygesen LC, Laursen B, Magyari M.

Eur J Neurol. 2017 Jun;24(6):825-834. doi: 10.1111/ene.13297.

PMID:
28544411
9.

Genetic burden of MS risk variants distinguish patients from healthy individuals but are not associated with disease activity.

Søndergaard HB, Petersen ER, Magyari M, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2017 Apr;13:25-27. doi: 10.1016/j.msard.2017.01.015. Epub 2017 Jan 31.

PMID:
28427696
10.

Age at Menarche and Risk of Multiple Sclerosis: A Prospective Cohort Study Based on the Danish National Birth Cohort.

Nielsen NM, Harpsøe M, Simonsen J, Stenager E, Magyari M, Koch-Henriksen N, Baker JL, Hjalgrim H, Frisch M, Bager P.

Am J Epidemiol. 2017 Apr 15;185(8):712-719. doi: 10.1093/aje/kww160.

PMID:
28369233
11.

Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort.

Thormann A, Koch-Henriksen N, Laursen B, Sørensen PS, Magyari M.

Mult Scler Relat Disord. 2016 Nov;10:181-186. doi: 10.1016/j.msard.2016.10.008. Epub 2016 Oct 29.

PMID:
27919487
12.

Early safety and efficacy of fingolimod treatment in Denmark.

Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen PS, Oturai AB.

Acta Neurol Scand. 2017 Jan;135(1):129-133. doi: 10.1111/ane.12573. Epub 2016 Mar 8.

PMID:
27910101
13.

Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.

Nielsen NM, Munger KL, Koch-Henriksen N, Hougaard DM, Magyari M, Jørgensen KT, Lundqvist M, Simonsen J, Jess T, Cohen A, Stenager E, Ascherio A.

Neurology. 2017 Jan 3;88(1):44-51. doi: 10.1212/WNL.0000000000003454. Epub 2016 Nov 30.

14.

The Danish Multiple Sclerosis Treatment Register.

Magyari M, Koch-Henriksen N, Sørensen PS.

Clin Epidemiol. 2016 Oct 25;8:549-552. eCollection 2016. Review.

15.

Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.

Thormann A, Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

J Neurol. 2016 Dec;263(12):2484-2493. Epub 2016 Oct 3.

PMID:
27699465
16.

Employment, disability pension and income for children with parental multiple sclerosis.

Moberg JY, Laursen B, Koch-Henriksen N, Thygesen LC, Brødsgaard A, Soelberg Sørensen P, Magyari M.

Mult Scler. 2017 Jul;23(8):1148-1156. doi: 10.1177/1352458516672016. Epub 2016 Sep 28.

PMID:
27682230
17.

Shift work at young age is associated with increased risk of multiple sclerosis in a Danish population.

Gustavsen S, Søndergaard HB, Oturai DB, Laursen B, Laursen JH, Magyari M, Ullum H, Larsen MH, Sellebjerg F, Oturai AB.

Mult Scler Relat Disord. 2016 Sep;9:104-9. doi: 10.1016/j.msard.2016.06.010. Epub 2016 Jun 27.

PMID:
27645354
18.

Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study.

Moberg JY, Magyari M, Koch-Henriksen N, Thygesen LC, Laursen B, Soelberg Sørensen P.

J Neurol. 2016 Nov;263(11):2229-2237. Epub 2016 Aug 19.

PMID:
27541043
19.

High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.

Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, Börnsen L, Romme Christensen J, Ratzer R, Siebner HR, Laursen B, Soelberg Sorensen P.

Mult Scler. 2017 Apr;23(5):675-685. doi: 10.1177/1352458516661048. Epub 2016 Aug 5.

PMID:
27481206
20.

A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.

Koch-Henriksen N, Magyari M, Sellebjerg F, Soelberg Sørensen P.

Mult Scler. 2017 Feb;23(2):234-241. doi: 10.1177/1352458516643393. Epub 2016 Jul 11.

PMID:
27055806
21.

Gender differences in multiple sclerosis epidemiology and treatment response.

Magyari M.

Dan Med J. 2016 Mar;63(3). pii: B5212. Review.

PMID:
26931196
22.

Self-rated health in women prior to clinical onset of multiple sclerosis: A study within the Danish National Birth Cohort.

Nielsen NM, Harpsøe MC, Simonsen J, Stenager E, Magyari M, Koch-Henriksen N, Frisch M, Bager P.

Mult Scler. 2016 Oct;22(11):1444-1451. Epub 2016 Jan 8.

PMID:
26746810
23.

Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.

Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H.

Ann Rheum Dis. 2016 Apr;75(4):785-6. doi: 10.1136/annrheumdis-2015-208490. Epub 2015 Dec 23. No abstract available.

PMID:
26698850
24.

Physical and social environment and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler Relat Disord. 2014 Sep;3(5):600-6. doi: 10.1016/j.msard.2014.07.002. Epub 2014 Jul 21.

PMID:
26265272
25.

Role of socio-economic and reproductive factors in the risk of multiple sclerosis.

Magyari M.

Acta Neurol Scand. 2015;132(199):20-3. doi: 10.1111/ane.12426. Review.

PMID:
26046554
26.

Registers of multiple sclerosis in Denmark.

Koch-Henriksen N, Magyari M, Laursen B.

Acta Neurol Scand. 2015;132(199):4-10. doi: 10.1111/ane.12424. Review.

PMID:
26046552
27.

Gender effects on treatment response to interferon-beta in multiple sclerosis.

Magyari M, Koch-Henriksen N, Laursen B, Sørensen PS.

Acta Neurol Scand. 2014 Dec;130(6):374-9. doi: 10.1111/ane.12277. Epub 2014 Sep 10.

PMID:
25208455
28.

The use of valproic acid and multiple sclerosis.

Nielsen NM, Svanström H, Stenager E, Magyari M, Koch-Henriksen N, Pasternak B, Hviid A.

Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):262-8. doi: 10.1002/pds.3692. Epub 2014 Aug 11.

PMID:
25111895
29.

Acute headache and persistent headache attributed to cervical artery dissection: Field testing of ICHD-III beta.

Schytz HW, Ashina M, Magyari M, Larsen VA, Olesen J, Iversen HK.

Cephalalgia. 2014 Aug;34(9):712-716. Epub 2014 Feb 5.

PMID:
24500814
30.

Gender and autoimmune comorbidity in multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler. 2014 Aug;20(9):1244-51. doi: 10.1177/1352458514521515. Epub 2014 Feb 5.

PMID:
24500604
31.

Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases.

Theibich A, Dreyer L, Magyari M, Locht H.

Clin Rheumatol. 2014 May;33(5):719-23. doi: 10.1007/s10067-013-2419-8. Epub 2013 Nov 8.

PMID:
24202614
32.

The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution.

McDowell A, Nagy I, Magyari M, Barnard E, Patrick S.

PLoS One. 2013 Sep 13;8(9):e70897. doi: 10.1371/journal.pone.0070897. eCollection 2013.

33.

Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study).

Magyari M, Bach Søndergaard H, Sellebjerg F, Soelberg Sørensen P.

Mult Scler Relat Disord. 2013 Apr;2(2):141-6. doi: 10.1016/j.msard.2012.10.001. Epub 2012 Dec 11.

PMID:
25877635
34.

Reproduction and the risk of multiple sclerosis.

Magyari M, Koch-Henriksen N, Pfleger CC, Sørensen PS.

Mult Scler. 2013 Oct;19(12):1604-9. doi: 10.1177/1352458513481397. Epub 2013 Mar 18.

PMID:
23508651
35.

Novel heterozygous nonsense mutation of the OPTN gene segregating in a Danish family with ALS.

Tümer Z, Bertelsen B, Gredal O, Magyari M, Nielsen KC, Lucamp, Grønskov K, Brøndum-Nielsen K.

Neurobiol Aging. 2012 Jan;33(1):208.e1-5. doi: 10.1016/j.neurobiolaging.2011.07.001. Epub 2011 Aug 26.

PMID:
21852022
36.

[Neurosarcoidosis--different manifestations].

Magyari M, Frederiksen J.

Ugeskr Laeger. 2010 Nov 29;172(48):3344-5. Danish.

PMID:
21118667
37.

Hydrolytic behavior of 5alpha-hydroxy-11beta- and 5beta-hydroxy-11alpha-substituted 19-norsteroids.

Francsics-Czinege E, Tuba Z, Molnár C, Horváth J, Csörgei J, Visky G, Balogh G, Mák M, Hegedus B, Magyari M, Horváth J.

Steroids. 2003 Oct;68(9):739-49.

PMID:
14625006
38.

[Iodine deficiency in cardiovascular diseases].

Molnár I, Magyari M, Stief L.

Orv Hetil. 1998 Aug 30;139(35):2071-3. Hungarian.

PMID:
9755626
39.

Mitochondrial mutation as a probable causative factor in familial progressive tubulointerstitial nephritis.

Zsurka G, Ormos J, Iványi B, Túri S, Endreffy E, Magyari M, Sonkodi S, Venetianer P.

Hum Genet. 1997 Apr;99(4):484-7.

PMID:
9099838
40.

[Prostacyclin-like activity modifying plasma factors in diabetic microangiopathy].

Magyari M, Túri S, Csanálosi-Németh M.

Fortschr Ophthalmol. 1990;87(3):269-73. German.

PMID:
2115854
41.

Plasma factors influencing prostacyclin-like activity in patients with diabetic microangiopathy.

Turi S, Magyari M, Nemeth M, Bereczky C.

Prostaglandins Leukot Essent Fatty Acids. 1988 Mar;31(3):107-11.

PMID:
3287394
42.

[Plasma factors influencing prostacyclin-like activity in diabetic microangiopathies].

Túri S, Magyari M, Csalánosiné NM.

Orv Hetil. 1987 Jun 21;128(25):1311-5. Hungarian. No abstract available.

PMID:
3302816

Supplemental Content

Loading ...
Support Center